Skip to main content
Erschienen in: Endocrine 2/2024

12.02.2024 | Original Article

Diagnosis of hepatic steatosis and steatohepatitis in people with new-onset type 2 diabetes: a multidisciplinary approach

verfasst von: L. Barana, A. Nelva, P. Scivetti, M. Costanzo, C. G. Fanelli

Erschienen in: Endocrine | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Aims

Non-Alcoholic-Fatty-Liver-Disease (NAFLD) is the most common cause of chronic liver disease in Western countries; closely linked to obesity and type 2 diabetes (T2DM), it is an additional cardiovascular risk factor. The aim of this study is to investigate the prevalence of NAFLD at T2DM onset.

Methods

122 newly diagnosed T2DM patients were enroled; NAFLD was diagnosed using ultrasound and fibrosis risk calculated with an FIB4-score. Intermediate and high-risk patients were referred to a hepatologist and underwent transient elastography (TE).

Results

At T2DM diagnosis, 25% of patients were overweight, 47% were obese; ultrasound steatosis was present in 79% of patients; the average FIB-4 score was 1.4 (0.7). The NAFLD population was characterised by higher presence of obesity (60%, p 0.06); hypertension (56%, p 0.00); AST (26.3 (23.6) UI/L; p 0.00); ALT (49.3(41.0) UI/L p 0.00); FIB-4 score (1.6 (0.8); p 0.00). Among patients referred to a hepatologist, at TE, 65% had severe steatosis, 22% significant fibrosis and 25% advanced fibrosis.

Conclusion

This is the first proposal of a NAFLD screening model at T2DM diagnosis. The high prevalence of fibrosis found at the early stage T2DM confirms the compelling need for early management of NAFLD through cost-effective screening and long-term monitoring algorithms.
Literatur
1.
Zurück zum Zitat F. Kanwal, J.H. Shubrook, Z. Younossi, Y. Natarajan, E. Bugianesi, M.E. Rinella, et al. Preparing for the NASH epidemic: A call to action. Metabolism. 122, 154822 (2021) F. Kanwal, J.H. Shubrook, Z. Younossi, Y. Natarajan, E. Bugianesi, M.E. Rinella, et al. Preparing for the NASH epidemic: A call to action. Metabolism. 122, 154822 (2021)
2.
Zurück zum Zitat A.M. Moon, A.G. Singal, E.B. Tapper, Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin. Gastroenterol. Hepatol. 18, 2650–2666 (2020). A.M. Moon, A.G. Singal, E.B. Tapper, Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin. Gastroenterol. Hepatol. 18, 2650–2666 (2020).
3.
Zurück zum Zitat E.E. Powell, V.W.S. Wong, M. Rinella, Non-alcoholic fatty liver disease. Lancet 397, 2212–2224 (2021)CrossRefPubMed E.E. Powell, V.W.S. Wong, M. Rinella, Non-alcoholic fatty liver disease. Lancet 397, 2212–2224 (2021)CrossRefPubMed
5.
Zurück zum Zitat D. Schuppan, R. Surabattula, X.Y. Wang, Determinants of fibrosis progression and regression in NASH. J. Hepatol. 68, 238–250 (2018)CrossRefPubMed D. Schuppan, R. Surabattula, X.Y. Wang, Determinants of fibrosis progression and regression in NASH. J. Hepatol. 68, 238–250 (2018)CrossRefPubMed
6.
Zurück zum Zitat Z. Younossi, F. Tacke, M. Arrese, B. Chander Sharma, I. Mostafa, E. Bugianesi et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatol. John Wiley Sons Inc. 69, 2672–2682 (2019) Z. Younossi, F. Tacke, M. Arrese, B. Chander Sharma, I. Mostafa, E. Bugianesi et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatol. John Wiley Sons Inc. 69, 2672–2682 (2019)
7.
Zurück zum Zitat Z.M. Younossi, P. Golabi, L. de Avila, J.M. Paik, M. Srishord, N. Fukui et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J. Hepatol. 71(4), 793–801 (2019)CrossRefPubMed Z.M. Younossi, P. Golabi, L. de Avila, J.M. Paik, M. Srishord, N. Fukui et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J. Hepatol. 71(4), 793–801 (2019)CrossRefPubMed
8.
Zurück zum Zitat G. Targher, Is it time for non-alcoholic fatty liver disease screening in patients with type 2 diabetes mellitus? Hepatobiliary Surg. Nutr. 9(2), 239–241 (2020)CrossRefPubMedPubMedCentral G. Targher, Is it time for non-alcoholic fatty liver disease screening in patients with type 2 diabetes mellitus? Hepatobiliary Surg. Nutr. 9(2), 239–241 (2020)CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat A.E. Morrison, F. Zaccardi, K. Khunti, M.J. Davies, Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis. Liver Int. 39(3), 557–567 (2019)CrossRefPubMed A.E. Morrison, F. Zaccardi, K. Khunti, M.J. Davies, Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis. Liver Int. 39(3), 557–567 (2019)CrossRefPubMed
11.
Zurück zum Zitat A. Lonardo, F. Nascimbeni, A. Mantovani, G. Targher, Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J. Hepatol. 68, 335–352 (2018)CrossRefPubMed A. Lonardo, F. Nascimbeni, A. Mantovani, G. Targher, Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J. Hepatol. 68, 335–352 (2018)CrossRefPubMed
12.
Zurück zum Zitat E. Buzzetti, M. Pinzani, E.A. Tsochatzis, The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65(8), 1038–1048 (2016)CrossRefPubMed E. Buzzetti, M. Pinzani, E.A. Tsochatzis, The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65(8), 1038–1048 (2016)CrossRefPubMed
13.
Zurück zum Zitat M. Eslam, P.N. Newsome, S.K. Sarin, Q.M. Anstee, G. Targher, M. Romero-Gomez et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 73, 202–209 (2020)CrossRefPubMed M. Eslam, P.N. Newsome, S.K. Sarin, Q.M. Anstee, G. Targher, M. Romero-Gomez et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 73, 202–209 (2020)CrossRefPubMed
15.
Zurück zum Zitat S. Ciardullo, E. Muraca, S. Perra, E. Bianconi, F. Zerbini, A. Oltolini et al. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. BMJ Open Diab Res Care 8, 904 (2020). http://drc.bmj.com/ S. Ciardullo, E. Muraca, S. Perra, E. Bianconi, F. Zerbini, A. Oltolini et al. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. BMJ Open Diab Res Care 8, 904 (2020). http://​drc.​bmj.​com/​
16.
Zurück zum Zitat G. Marchesini, C.P. Day, J.F. Dufour, A. Canbay, V. Nobili, V. Ratziu et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64(6), 1388–1402 (2016). Jun 1CrossRef G. Marchesini, C.P. Day, J.F. Dufour, A. Canbay, V. Nobili, V. Ratziu et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64(6), 1388–1402 (2016). Jun 1CrossRef
17.
Zurück zum Zitat J. Zheng, H. Guo, J. Zeng, Z. Huang, B. Zheng, J. Ren et al. Two-dimensional shear-wave elastography and conventional us: The optimal evaluation of liver fibrosis and cirrhosis. Radiology 275(1), 290–300 (2015)CrossRefPubMed J. Zheng, H. Guo, J. Zeng, Z. Huang, B. Zheng, J. Ren et al. Two-dimensional shear-wave elastography and conventional us: The optimal evaluation of liver fibrosis and cirrhosis. Radiology 275(1), 290–300 (2015)CrossRefPubMed
18.
Zurück zum Zitat K. Kozłowska-Petriczko, E. Wunsch, J. Petriczko, W.K. Syn, P. Milkiewicz. Diagnostic accuracy of non-imaging and ultrasound-based assessment of hepatic steatosis using controlled attenuation parameter (Cap) as reference. J Clin Med. 10(7) 1507 (2021) K. Kozłowska-Petriczko, E. Wunsch, J. Petriczko, W.K. Syn, P. Milkiewicz. Diagnostic accuracy of non-imaging and ultrasound-based assessment of hepatic steatosis using controlled attenuation parameter (Cap) as reference. J Clin Med. 10(7) 1507 (2021)
19.
Zurück zum Zitat L. Castera, M. Friedrich-Rust, R. Loomba, Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterol. W. B. Saunders 156, 1264–1281.e4 (2019) L. Castera, M. Friedrich-Rust, R. Loomba, Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterol. W. B. Saunders 156, 1264–1281.e4 (2019)
21.
Zurück zum Zitat E. Reginato, R. Pippi, C. Aiello, E.S. Tomaro, C. Ranucci, L. Buratta et al. Clinical Medicine Effect of Short Term Intensive Lifestyle Intervention on Hepatic Steatosis Indexes in Adults with Obesity and/or Type 2 Diabetes. Available from: www.mdpi.com/journal/jcm E. Reginato, R. Pippi, C. Aiello, E.S. Tomaro, C. Ranucci, L. Buratta et al. Clinical Medicine Effect of Short Term Intensive Lifestyle Intervention on Hepatic Steatosis Indexes in Adults with Obesity and/or Type 2 Diabetes. Available from: www.​mdpi.​com/​journal/​jcm
23.
Zurück zum Zitat E. Vilar-Gomez, Y. Martinez-Perez, L. Calzadilla-Bertot, A. Torres-Gonzalez, B. Gra-Oramas, L. Gonzalez-Fabian et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149(2), 367–378.e5 (2015)CrossRefPubMed E. Vilar-Gomez, Y. Martinez-Perez, L. Calzadilla-Bertot, A. Torres-Gonzalez, B. Gra-Oramas, L. Gonzalez-Fabian et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149(2), 367–378.e5 (2015)CrossRefPubMed
24.
Zurück zum Zitat S.L. Attia, S. Softic, M. Mouzaki, Evolving Role for Pharmacotherapy in NAFLD/NASH. Clin. Transl. Sci. Blackwell Publ. Ltd 14, 11–19 (2021)CrossRef S.L. Attia, S. Softic, M. Mouzaki, Evolving Role for Pharmacotherapy in NAFLD/NASH. Clin. Transl. Sci. Blackwell Publ. Ltd 14, 11–19 (2021)CrossRef
25.
Zurück zum Zitat A. Mantovani, C.D. Byrne, G. Targher, Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol. Hepatol. 7, 367–378 (2022)CrossRefPubMed A. Mantovani, C.D. Byrne, G. Targher, Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol. Hepatol. 7, 367–378 (2022)CrossRefPubMed
26.
Zurück zum Zitat G. Targher, K.E. Corey, C.D. Byrne, M. Roden, The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments. Nat. Rev. Gastroenterol. Hepatol. Nat. Res. 18, 599–612 (2021)CrossRef G. Targher, K.E. Corey, C.D. Byrne, M. Roden, The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments. Nat. Rev. Gastroenterol. Hepatol. Nat. Res. 18, 599–612 (2021)CrossRef
27.
Zurück zum Zitat K. Cusi, S. Isaacs, D. Barb, R. Basu, S. Caprio, W.T. Garvey et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr. Pract. 28(5), 528–562 (2022)CrossRefPubMed K. Cusi, S. Isaacs, D. Barb, R. Basu, S. Caprio, W.T. Garvey et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr. Pract. 28(5), 528–562 (2022)CrossRefPubMed
28.
Zurück zum Zitat K. Cusi, Time to include nonalcoholic steatohepatitis in the management of patients with type 2 diabetes. Diabetes Care 43(2), 275–279 (2020)CrossRefPubMed K. Cusi, Time to include nonalcoholic steatohepatitis in the management of patients with type 2 diabetes. Diabetes Care 43(2), 275–279 (2020)CrossRefPubMed
29.
Zurück zum Zitat J.V. Lazarus, M. Ekstedt, G. Marchesini, J. Mullen, K. Novak, J.M. Pericàs et al. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. J. Hepatol. 72(1), 14–24 (2020)CrossRefPubMed J.V. Lazarus, M. Ekstedt, G. Marchesini, J. Mullen, K. Novak, J.M. Pericàs et al. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. J. Hepatol. 72(1), 14–24 (2020)CrossRefPubMed
31.
Zurück zum Zitat J.V. Lazarus, H.E. Mark, A.M. Allen, J.P. Arab, P. Carrieri, M. Noureddin, W. Alazawi, N. Alkhouri, S.A. Alqahtani, M. Arrese, R. Bataller, T. Berg, P.N. Brennan, P. Burra, G.E. Castro-Narro, H. Cortez-Pinto, K. Cusi, N. Dedes, A. Duseja, S.M. Francque; Healthy Livers, Healthy Lives Collaborators, A global research priority agenda to advance public health responses to fatty liver disease. J. Hepatol. 79(3), 618–634 (2023). https://doi.org/10.1016/j.jhep.2023.04.035CrossRefPubMed J.V. Lazarus, H.E. Mark, A.M. Allen, J.P. Arab, P. Carrieri, M. Noureddin, W. Alazawi, N. Alkhouri, S.A. Alqahtani, M. Arrese, R. Bataller, T. Berg, P.N. Brennan, P. Burra, G.E. Castro-Narro, H. Cortez-Pinto, K. Cusi, N. Dedes, A. Duseja, S.M. Francque; Healthy Livers, Healthy Lives Collaborators, A global research priority agenda to advance public health responses to fatty liver disease. J. Hepatol. 79(3), 618–634 (2023). https://​doi.​org/​10.​1016/​j.​jhep.​2023.​04.​035CrossRefPubMed
32.
Zurück zum Zitat Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO), Members of the guidelines panel, Coordinator, AISF Members, SID Members, SIO Members, & Metodologists, Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Digestive Liver Dis. 54(2), 170–182 (2022). https://doi.org/10.1016/j.dld.2021.04.029 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO), Members of the guidelines panel, Coordinator, AISF Members, SID Members, SIO Members, & Metodologists, Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Digestive Liver Dis. 54(2), 170–182 (2022). https://​doi.​org/​10.​1016/​j.​dld.​2021.​04.​029
36.
Zurück zum Zitat G. Russo, A. Rocca, V. Manicardi, R. Candido, M. Cavallo, I. Crisci, et al. La steatosi epatica non alcolica (NAFLD) nel diabete di tipo 2 analisi stratificata per età, sesso e BMI, 2022 G. Russo, A. Rocca, V. Manicardi, R. Candido, M. Cavallo, I. Crisci, et al. La steatosi epatica non alcolica (NAFLD) nel diabete di tipo 2 analisi stratificata per età, sesso e BMI, 2022
37.
Zurück zum Zitat A. Mantovani, T. Turino, M.G. Lando, K. Gjini, C.D. Byrne, C. Zusi et al. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. Diabetes Metab. 46(4), 296–303 (2020)CrossRefPubMed A. Mantovani, T. Turino, M.G. Lando, K. Gjini, C.D. Byrne, C. Zusi et al. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. Diabetes Metab. 46(4), 296–303 (2020)CrossRefPubMed
38.
Zurück zum Zitat W.D. Li, K.F. Fu, G.M. Li, Y.S. Lian, A.M. Ren, Y.J. Chen et al. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus. World J. Gastroenterol. 21(32), 9607–9613 (2015)CrossRefPubMedPubMedCentral W.D. Li, K.F. Fu, G.M. Li, Y.S. Lian, A.M. Ren, Y.J. Chen et al. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus. World J. Gastroenterol. 21(32), 9607–9613 (2015)CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat J. Park, G. Kim, B.S. Kim, K.D. Han, S. Yoon Kwon, S. Hee Park, et al. The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study. Available from: https://doi.org/10.1186/s12933-022-01483-y J. Park, G. Kim, B.S. Kim, K.D. Han, S. Yoon Kwon, S. Hee Park, et al. The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study. Available from: https://​doi.​org/​10.​1186/​s12933-022-01483-y
40.
Zurück zum Zitat G. Targher, A. Mantovani, A. Csermely, G. Petracca, G. Beatrice, K.E. Corey et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Diabetes Metabol. 2021. Available from: www.thelancet.com/gastrohep G. Targher, A. Mantovani, A. Csermely, G. Petracca, G. Beatrice, K.E. Corey et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Diabetes Metabol. 2021. Available from: www.​thelancet.​com/​gastrohep
42.
Zurück zum Zitat G. Zoppini, U. Fedeli, N. Gennaro, M. Saugo, G. Targher, E. Bonora, Mortality from chronic liver diseases in diabetes. Am. J. Gastroenterol. 109(7), 1020–1025 (2014)CrossRefPubMed G. Zoppini, U. Fedeli, N. Gennaro, M. Saugo, G. Targher, E. Bonora, Mortality from chronic liver diseases in diabetes. Am. J. Gastroenterol. 109(7), 1020–1025 (2014)CrossRefPubMed
44.
Zurück zum Zitat O. Lavynenko, M. Abdul-Ghani, M. Alatrach et al. Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). Diabetes Obes. Metab. 24(5), 899–907 (2022). https://doi.org/10.1111/dom.14650CrossRefPubMed O. Lavynenko, M. Abdul-Ghani, M. Alatrach et al. Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). Diabetes Obes. Metab. 24(5), 899–907 (2022). https://​doi.​org/​10.​1111/​dom.​14650CrossRefPubMed
45.
Zurück zum Zitat A. Gastaldelli, K. Cusi, L. Fernández Landó, R. Bray, B. Brouwers, Á. Rodríguez, Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 10(6), 393–406 (2022). https://doi.org/10.1016/S2213-8587(22)00070-5CrossRefPubMed A. Gastaldelli, K. Cusi, L. Fernández Landó, R. Bray, B. Brouwers, Á. Rodríguez, Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 10(6), 393–406 (2022). https://​doi.​org/​10.​1016/​S2213-8587(22)00070-5CrossRefPubMed
49.
Zurück zum Zitat M.E. Rinella, J.V. Lazarus, V. Ratziu, S.M. Francque, A.J. Sanyal, F. Kanwal, D. Romero, M.F. Abdelmalek, Q.M. Anstee, J.P. Arab, M. Arrese, R. Bataller, U. Beuers, J. Boursier, E. Bugianesi, C.D. Byrne, G.E. Castro Narro, A. Chowdhury, H. Cortez-Pinto, D.R. Cryer; NAFLD Nomenclature consensus group, A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79(6), 1542–1556 (2023). https://doi.org/10.1016/j.jhep.2023.06.003CrossRefPubMed M.E. Rinella, J.V. Lazarus, V. Ratziu, S.M. Francque, A.J. Sanyal, F. Kanwal, D. Romero, M.F. Abdelmalek, Q.M. Anstee, J.P. Arab, M. Arrese, R. Bataller, U. Beuers, J. Boursier, E. Bugianesi, C.D. Byrne, G.E. Castro Narro, A. Chowdhury, H. Cortez-Pinto, D.R. Cryer; NAFLD Nomenclature consensus group, A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79(6), 1542–1556 (2023). https://​doi.​org/​10.​1016/​j.​jhep.​2023.​06.​003CrossRefPubMed
51.
Zurück zum Zitat A. Mantovani, G. Petracca, G. Beatrice, H. Tilg, C.D. Byrne, G. Targher, Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut 70(5), 962–969 (2021). https://gut.bmj.com/content/70/5/962 A. Mantovani, G. Petracca, G. Beatrice, H. Tilg, C.D. Byrne, G. Targher, Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut 70(5), 962–969 (2021). https://​gut.​bmj.​com/​content/​70/​5/​962
Metadaten
Titel
Diagnosis of hepatic steatosis and steatohepatitis in people with new-onset type 2 diabetes: a multidisciplinary approach
verfasst von
L. Barana
A. Nelva
P. Scivetti
M. Costanzo
C. G. Fanelli
Publikationsdatum
12.02.2024
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2024
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-024-03715-5

Weitere Artikel der Ausgabe 2/2024

Endocrine 2/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.